Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes

Diabetes Care

Volumn 37, Issue 9, 2014, Pages 2593-2600

  Gordin, Daniel ^a   Forsblom, Carol ^a   Panduru, Nicolae M ^b   Thomas, Merlin C ^c   Bjerre, Mette ^d   Soro Paavonen, Aino ^a   Tolonen, Nina ^a   Sandholm, Niina ^a   Flyvbjerg, Allan ^d   Harjutsalo, Valma ^a,e   Groop, Per Henrik ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN A1C; OSTEOPONTIN; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; BODY MASS; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; FRAMMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; IMPLANT REGISTRY; INCIDENCE; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; LIMIT OF DETECTION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROALBUMINURIA; MORTALITY; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RATING SCALE; RETINA DISEASE; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETIC NEPHROPATHIES; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OSTEOPONTIN; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84906670386     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0065     Document Type: Article

References (31)

1. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontinda molecule for all seasons. QJM 2002;95:3-13
2. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997;17:1-15
3. Yamate T, Kohri K, Umekawa T, Iguchi M, Kurita T. Osteopontin antisense oligonucleotide inhibits adhesion of calcium oxalate crystals in Madin-Darby canine kidney cell. J Urol 1998; 160:1506-1512
4. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998;101:1468-1478
5. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 1993;13:225-246
6. Kiefer FW, Zeyda M, Gollinger K, et al. Neutralization of osteopontin inhibits obesityinduced inflammation and insulin resistance. Diabetes 2010;59:935-946
7. Wexler L, Brundage B, Crouse J, et al.; Writing Group. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Circulation 1996;94:1175-1192
8. Takemoto M, Yokote K, Nishimura M, et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:624-628
9. Kase S, Yokoi M, Saito W, et al. Increased osteopontin levels in the vitreous of patients with diabetic retinopathy. Ophthalmic Res 2007;39:143-147
10. Yamaguchi H, Igarashi M, Hirata A, et al. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 2004;51:499-504
11. Minoretti P, Falcone C, Calcagnino M, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802-807
12. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28:2901-2907
13. Groop PH, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts allcause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658
14. Hietala K, Wadén J, Forsblom C, et al.; FinnDiane Study Group. HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. Diabetologia 2013;56:737-745
15. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health 2012;40:505-515
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl. 1):S1-S266
17. Levey AS, Coresh J, Greene T, et al.; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254
18. WilsonPW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847
19. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009;150:795-802
20. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001;104:1863-1867
21. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
22. Forsblom C, Harjutsalo V, Thorn LM, et al.; FinnDiane Study Group. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2011;22:537-544
23. ScatenaM, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007;27:2302-2309
24. Parrish AR, Ramos KS. Osteopontin mRNA expression in a chemically-induced model of atherogenesis. Ann N Y Acad Sci 1995;760: 354-356
25. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328
26. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-2918
27. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-663
28. Salem M, El Behery S, Adly A, Khalil D, El Hadidi E. Early predictors of myocardial disease in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2009;10: 513-521
29. Gupta S, de Lemos JA. Use and misuse of cardiac troponins in clinical practice. Prog Cardiovasc Dis 2007;50:151-165
30. James S, Armstrong P, Califf R, et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med 2003;115:178-184
31. Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a communitybased cohort study. Circulation 2006;113: 1071-1078